Anal Canal Cancer, Anal Canal Cancer Stage III, Anal Cancer, Anal Squamous Cell Carcinoma
Conditions
Keywords
Anal Squamous Cell Carcinoma, Radiochemotherapy, PD-1
Brief summary
This is a phase III, multi-center, double-blind randomized controlled trial assessing the efficacy and safety of concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT combined with PD-1 antibody Sintilimab for locally advanced anal canal squamous carcinoma patients, by comparing an experiment group (traditional chemoradiotherapy with PD-1 antibody Sintilimab) with a control group (traditional treatment without Sintilimab).
Interventions
DRUGPD-1 inhibitor
Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
RADIATIONconcurrent chemoradiotherapy
Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
Sponsors
Sixth Affiliated Hospital, Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histology identified anal canal squamous carcinoma, 2. Aged 18 to 75, 3. Clinical staging III, Eastern Cooperative Oncology Group 0-2 score, 4. The Staging method: All patients undergoing rectal anus palpation, high resolution MRI and chest-abdominal enhanced CT, clinical data should be re-evaluated and inclusive by center evaluation group when there is contradictory staging, distant metastasis were excluded by chest-abdominal enhanced CT and pelvic enhanced MRI, 5. No previous anal canal surgery or anal tumor resection (except for biopsy), 6. No previous chemotherapy or pelvic radiotherapy history, 7. No biopharmaceutical treatment history (such as monoclonal antibody), immunotherapy (such as anti PD-1antibody, anti PD-L1 antibody, anti PD-L2 antibody or anti CTLA-4), or other research drug treatment in the previous 5 years, 8. Adequate bone marrow, liver, and kidney function, 9. Clinical complete response (cCR) (Chest, abdominal and pelvic enhanced CT or pelvic enhanced MRI or PET/CT), 10. Informed consent assigned, Final inclusion criteria, 11. Non-pregnant or breast-feeding women, 12. No other malignant disease within 5 years before diagnosis of anal cancer squamous carcinoma (except endocervical cancer in situ or skin basal cell carcinoma which had been cured); no other malignant disease beside anal cancer squamous carcinoma, 13. No other serious disease leading to shortened survival.
Exclusion criteria
1. Diagnosed as stage I-II and well differentiated squamous cell carcinoma, 2. Distant metastasis, 3. Received radiation therapy in abdominal or pelvic regions, 4. Pregnant, lactating woman patient or fertile but lacks adequate contraceptives, 5. Arrhythmia need anti-arrhythmia treatment (except β-blocking agent or Digoxin), symptomatic coronary heart disease or myocardial ischemia (myocardial infarction within 6 months) or congestive heart-failure (CHF) \> New York Heart Association grade II, 6. Severe hypertension not well controlled by drugs, 7. Active phase of chronic hepatitis B or hepatitis C (high copies of virus DNA), 8. Patients with active tuberculosis (TB) are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year before screening, 9. Other active clinical severe infection (NCI-CTCAE (version 4.0) ), 10. Dyscrasia, organ dysfunction, 11. Known or suspicious allergy to any research-related drugs, 12. Epilepsy needs treatments (Steroid or anti-epilepsy therapy), 13. Other malignant tumor history within 5 years, 14. Drug abuse and medical, psychological, or social factors that may interfere with patients' participation in the study or affect the evaluation of the study, 15. Patients have any active autoimmune diseases or a history of autoimmune diseases (including but not restricted: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and decreased thyroid function; patients with vitiligo or with complete remission of asthma in childhood and without any intervention in adulthood may be included; patients with asthma requiring bronchodilators intervention are not included, 16. Any anti-infection vaccine 4 weeks before inclusion, 17. Long-term exposure to immune-suppressor, combination of systemic or topical use of corticosteroids (dose\>10mg/day prednisolone or equivalent hormone), 18. Any unstable state might endanger the patients' safety and compliance, 19. Refuses to sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | from the end of treatment to 3 years after treatment | progression free survival |
| Overall survival | from the end of treatment to 3 years after treatment | overall survival |
| cCR rate | 6 months after treatment | cCR rate 6 months after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Colostomy rate | 2 year | colostomy rate |
| Local recurrence rate | from the end of treatment to 3 years after treatment | local recurrence rate |
| Acute toxicities | from the start of treatment to 3 months after treatment | acute toxicities according to the NCI CTCAE (version 4.0) |
| Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events | 1 year | Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events |
| Distant metastasis rate | from the end of treatment to 3 years after treatment | distant metastasis rate |
| cCR rate | 3 months after treatment | cCR rate 3 months after treatment |
| The rate of late toxicity according to the RTOG/EORTC scale | 3 years | The rate of late toxicity according to the RTOG/EORTC scale |
Countries
China
Contacts
Primary ContactXiang-bo Wan, PhD
Backup ContactFang He, MD
Outcome results
None listed